BCI 838

Drug Profile

BCI 838

Alternative Names: BCI-838

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Developer BrainCells
  • Class Antidepressants
  • Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Netherlands (PO)
  • 06 Dec 2012 Topline pharmacokinetic, pharmacodynamic and Adverse event data released by BrainCells Inc.
  • 08 May 2012 BrainCells completes a phase I trial in Healthy volunteers in Netherlands (NCT01548703)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top